Table 2 Descriptive statistics of the case control study

N

594

1188

Age at index date, median [IQR]

86.5 [80–89]

87 [81–90]

0.95

Sex Female, n (%)

203 (34.2)

406 (34.2)

–

Rx-risk comorbidity score^a,b, median [IQR]

7 [5–8]

6 [5–8]

< 0.001

 Hypertension^a, n (%)

241 (40.6)

544 (45.8)

0.04

 Congestive heart failure^a, n (%)

168 (28.3)

267 (22.5)

0.008

 Diabetes^a, n (%)

62 (10.4)

121 (10.2)

0.93

Co-morbid osteoarthritis, n (%)

403 (67.9)

859 (72.3)

0.053

 Controlled release paracetamol, n (%)

383 (64.5)

829 (69.8)

0.03

 Hospitalization with osteoarthritis, n (%)

66 (11.1)

124 (10.4)

0.68

Number of health service visits^a, median [IQR]

50 [32–74]

43 [27–61]

< 0.001

Statin use^c, n (%)

274 (46.3)

615 (51.8)

0.032

Days exposed, median [IQR]

66 [33–153]

66 [33–158]

0.33

 Proportion of time exposed during follow up, median [IQR]

0.276 [0.120–0.564]

0.264 [0.114–0.542]

0.35

 Chronic users^d, n (%)

332 (55.9%)

633 (53.3%)

0.32

Follow up (years), median [IQR]

0.99 [0.43–2.05]

1.00 [0.43–2.06]

0.99